In 2010, the European Patent Office (EPO) amended Rule 36 of the European Patent Convention to mandate that divisional applications could only be filed within two years after the first communication from the Examining Division of the EPO. After this two-year window, it was no longer possible to file divisional applications, except in extraordinary circumstances. […]
Assoc. for Molecular Path. et al. v. Myriad Genetics, Inc., No. 12-398 (U.S., June 13, 2013). The Supreme Court decided today that “[a] naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated” under 35 U.S.C. Section 101. Therefore, naturally occurring DNA sequences containing both intron and […]
The Denver Business Journal profiles Swanson & Bratschun, LLC, who teamed with another firm to win a prestigious contract to handle biotechnology patents for the National Institutes of Health for 10 years. View the complete article as a PDF.